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Abstract
Many investigations were carried out on the association between viruses and multiple sclerosis (MS). Indeed, early studies
reported the detections of neurotropic virus footprints in the CNS of patients with MS. In this study, sera from patients
affected by MS, other inflammatory (OIND) and non-inflammatory neurologic diseases (NIND) were analyzed for antibodies
against the polyomavirus, Simian Virus 40 (SV40). An indirect enzyme-linked immunosorbent assay (ELISA), with two
synthetic peptides, which mimic SV40 antigens, was employed to detect specific antibodies in sera from patients affected
by MS, OIND, NIND and healthy subjects (HS). Immunologic data indicate that in sera from MS patients antibodies against
SV40 mimotopes are detectable with a low prevalence, 6%, whereas in HS of the same mean age, 40 yrs, the prevalence was
22%. The difference is statistically significant (P = 0.001). Significant is also the difference between MS vs. NIND patients (6%
vs. 17%; P= 0.0254), whereas no significant difference was detected between MS vs OIND (6% vs 10%; P.0.05). The
prevalence of SV40 antibodies in MS patients is 70% lower than that revealed in HS.
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Introduction
Multiple sclerosis (MS) is a chronic human demyelinating
disease of the central nervous system (CNS) characterized by an
autoimmune pathogenic process in genetically predisposed indi-
viduals [1,2]. Although the etiology of MS is unknown, genetic and
environmental factors seem to play an important role.
Accumulating data, including animal study models, human
models of virus inducing demyelination, epidemiologic and
laboratory findings, have demonstrated that viruses and host
genetic factors can interact to cause immune-mediated demyelin-
ation [3,4]. Infectious agents are environmental factors potentially
involved in the MS onset. Specifically, ubiquitous viruses were
found associated with the development or exacerbation of MS,
including the herpesviruses (i) Epstein-Barr virus (EBV) [5,6,7,8],
(ii) human herpesvirus 6 (HHV-6) [9] and human endogenous
retrovirus (HERV) families [10]. Although the current evidence
supports a strong association between EBV and MS, the potential
causality of this herpesvirus remains to be established [11].
EBV has been investigated for its putative role in the MS onset.
Earlier studies found a higher prevalence of anti-EBV antibodies
in MS patients compared to controls [7,8]. At present, it cannot be
excluded that the abnormal response to EBV infection in MS
patients is a consequence, rather than a cause. It has been reported
that EBV cannot alone trigger the MS onset [7]. Further
molecular evidences are needed to assess the real involvement of
EBV in the MS onset.
HHV-6 strains A/B has been proposed as viral agents involved
in several autoimmune disorders (AD), including MS. HHV-6A
could participate in neuro-inflammation in the context of MS by
promoting inflammatory processes through CD46 binding [9].
HERV-Fc1, which sequences map in chromosome X, has been
associated with MS, mostly in Northern European populations.
Association of the HERV-Fc1 polymorphism rs391745 with bout-
onset MS susceptibility was also confirmed in Southern European
cohorts [10].
Polyomaviruses, including Simian Virus 40 (SV40) [12,13] have
been poorly investigated for their putative role in MS disease [14].
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SV40, a monkey neurotropic polyomavirus, is responsible for the
progressive multifocal leukoencephalopathy (PML) in immune-
compromised macaques [15,16] while in humans its footprints
have been detected in brain tumors and neurologic disorders
[17,18,19].
Recently, the development of specific and sensitive serologic test
for SV40 has been reported, which consists of an indirect ELISA
employing synthetic peptides as mimotopes/antigens of SV40 viral
capsid proteins (VPs). This immunologic assay was used to detect
specific serum antibodies against SV40 VPs in normal individuals
of different age [20,21,22]. Higher prevalence of SV40 antibodies
was detected in oncologic patients affected by glioblastoma
multiforme (GBM) [19], whereas SV40 sequences and large T
antigen expression were detected in human brain tumors
[23,24,25].
The complex interactions among the CNS, multiple infections
with different infectious agents occurring in the periphery or
within the CNS, and the immune response should be analyzed and
elucidated in order to understand the etiology of MS.
The objective of the present study was to investigate whether
serum samples from patients affected by MS, other OIND, NIND
and HS carry SV40-antibodies. Sera were analyzed by an indirect
ELISA employing synthetic peptides as mimotopes belonging to
the viral capsid proteins (VPs).
Results
Low prevalence of antibodies reacting with SV40
mimotopes in serum samples from multiple sclerosis
patients
Serum samples from MS patients were analyzed by indirect
ELISA for the presence of IgG class antibodies against SV40 VP
mimotopes/epitopes (Tables 1 and 2). The indirect ELISA was
employed to test serum samples of MS affected patients (mean age
= 37 yrs), which had been diluted at 1/20, for reactivity to SV40
epitopes from VP1, VP1 B peptide. Serum samples reacting with
the SV40 VP1 B mimotopes reached an overall prevalence of 9%.
Then, the same assay was addressed to detect IgG class serum
antibodies against SV40 VP2/3 epitopes, which are known as
VP2/3 C peptide. Serum samples reacted with the SV40 VP2/3 C
peptide with a similar prevalence, 13%, as had been detected
previously for the VP1 B peptide. Conversely, seronegative
samples for the SV40 VP1 B peptide failed to react with SV40
VP2/3 C epitopes. The exceptions were negligible represented by
a few serum samples, which were negative for VP1 B peptide,
while testing positive for VP2/3 C peptide, and vice-versa. The
difference was not statistically significant (P.0.05) (Table 1). The
different prevalence of responses/OD reading of B and C peptides
is probably due to the different immunogenicity of the two SV40
antigens. Indeed, the B peptide is present in the VP1 virion, in its
pentameric form, 360 times, whereas the C peptide of VP2/3 is
present in the virion 72 times [20].
As published before [19,20,21,22] in indirect ELISAs the
human peptide hNPS which is unrelated to SV40, was employed
as a negative control peptide to verify if, in our experimental
conditions, a non-specific reaction may occur with SV40-positive
and SV40-negative human and rabbit serum samples. Data
indicate that this negative control peptide does not react with
SV40-positive and SV40-negative sera. The OD value was usually
in the range of 0.088-0.098, which is consistent with the OD
background of both human and rabbit sera [19,20,21,22].
The two indirect ELISAs, with the two distinct VP B and C
peptides gave overlapping results, thus confirming the presence of
anti-SV40 VPs antibodies, although at low prevalence, in human
sera from patients affected by MS (Tables 1 and 2).
In our investigation only those samples found positive for both B
and C peptides were considered SV40-positive (Tables 1 and 2).
Altogether, our immunologic data indicate that combining the
SV40-positive sera (6/93), both for the VP1 B and VP2/3 C
peptides, the overall prevalence was 6% (Tables 2).
Control samples represented by sera from healthy subjects, with
a similar mean age of MS patients, 40 yrs, were investigated with
the same ELISA. Immunologic results indicated a prevalence 22%
in these healthy subjects (HS1) (Table 2). These results are in
agreement with previous immunologic data, obtained with other
cohorts of HS, with the same mean age [20]. Indeed, ELISA data
indicate that the prevalence of SV40 antibodies is similar in the
cohorts of individuals with the same age and gender, despite
coming from different regions in Italy. However, a decline of
prevalence was detected in elderly [21].
MS and HS1 serologic profiles of serum antibody reactivity to
SV40 mimitopes are shown in Figure 1.
SV40-positive sera, which were selected by the neutralization
assay as reported elsewhere [19,20] tested by indirect ELISA
diluted at 1/20 had a general cut-off, by spectrophotometric
reading, in the range of 0.18 OD. This cut-off represents in our
ELISA the value that discriminates SV40-negative (OD ,0.18)
from SV40-positive samples (OD.0.18).
ELISA data obtained with serum samples from OIND,
NIND patients and HS
In the second step of this investigation, indirect ELISA was
employed to test serum samples from OIND and NIND affected
patients, and healthy subjects (HS2), with a similar mean age of
these patients (51 yrs). Sera had been diluted at 1/20, for reactivity
to SV40 epitopes from VP1, VP1 B peptide and then from VP 2/
3, C peptide. Serum samples, which reacted with both SV40 VP1
B and VP2/3 mimotopes reached an overall prevalence of 10% in
OIND, 17% in NIND, whereas the control samples represented
by sera from HS2 the prevalence was 21%.
Serologic data obtained with the cohorts of HS1 and HS2 are in
agreement with those reported before with other cohorts of HS,
with the same mean age [20].
It is interesting to note that SV40 peptide C prevalence in these
samples is very similar to the data obtained with the same samples
for SV40 peptide B. OIND, NIND and HS2 serologic profiles of
serum antibody reactivity to SV40 mimotopes are shown in
Figure 1.
Discussion
SV40-antibody detection had been attempted in several studies
using serologic methods with SV40 antigens, but due to the high
homology among the three main Polyomaviruses (SV40, BKV and
JCV), the results were always affected by some cross-reactivity
[14,17,26,27,28,29].
Specific immunologic assays for the identification of SV40-
seropositive individuals/patients and serum antibody reactivity to
SV40 antigens are of paramount importance in revealing the
prevalence of SV40 infection in patients and normal subjects.
In this study, serum samples from patients affected by
neurologic diseases, including MS, together with those from
healthy individuals employed as controls, were analyzed for
exposure to SV40 infection. The indirect ELISA employed in this
study used specific SV40 antigens/mimotopes. Indeed, the
synthetic peptides from SV40 VP 1–3 employed mimic the
corresponding epitopes of the viral capsid peptides [19,20,21,22].
SV40 in OIND Patients
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Table 1. MS, OIND and NIND patients and healthy subjects.
Serum Subject (N) Female (%)






MS 66 37611.2 RR 78 6/78 (7)
(93) (13–68) SP 10 0/10
PP 5 0/5
OIND 50 53614.2 Inflammatory Demyelinating 34 2/34(6)




NIND 50 52616.8 ALS 8 2(25)
(81) (21–85) Dementia 6 0/6
MSA 1 0/1
Arteriovenous malformation 3 1/3(33)
Migraine 10 5/10(50)
Toxic encephalopathy 2 0/2
Epilepsy 4 0/4
Hereditary ataxia 3 1/3(33)
Brain Tumor 8 0/8
Hydrocephalus 2 0/2
Spondylotic myelopathy 4 0/4
Peripheral neuropathy 9 2/9(22)
Pseudotumor cerebri 2 1/2(50)
Funicular myelopathy 1 0/1
Stroke/TIA 18 2/18(11)
HS1 67 40611.7 Healthy subjects 180 40/180(22)
(180) (17–67)
HS2 50 51611.7 Healthy subjects 160 34/160(21)
(160) (18–81)
MS (Multiple Sclerosis); OIND (Other Inflammatory Neurologic Disease); NIND (Non Inflammatory Neurologic Disease); HS (Healthy Subjects); RR (Relapsing-Remitting): SP
(Secondary-Progressive); PP (Primary-Progressive); PML (Progressive Multifocal Leucoencephalopathy); ALS (Amyotrophic Lateral Sclerosis); MSA (Multiple System Atrophy);
TIA (Transient Ischemic Attack). Among SV40-positive patients, 2 OIND patients were found to be affected by Inflammatory Demyelinating, 3 patients were affected by
Meningitis/Ancephalitis/Myelitis and 3 by Comnnectivitis/Vasculitis. Among NIND patients SV40-positive were 2 patients affected by Amyotrophic Lateral Sclerosis (ALS), 1
by Arteriovenous Malformation, 1 by Hereditary Ataxia, 2 by Peripheral Neuropathy, 1 by Pseudotumor Cerebri and 2 by Transient Ischemic Attacks (TIA). The three MS
patients were affected by relapsing remitting MS forms.
doi:10.1371/journal.pone.0110923.t001
Table 2. Prevalence of immunoglobulin G antibodies reacting with Simian Virus 40 (SV40) viral protein (VP) mimotopes in serum
samples of patients affected by MS, OIND, NIND and HS‘.
Serum‘ sample Number of patients/subject Female % Number of positive samples (%)
VP B VP C VP B+C
MS 93 66 8 (9) 12 (13) 6 (6)*
HS1 180 67 63 (35) 52 (29) 40 (22)
OIND 77 50 20 (26) 11 (14) 8 (10)**
NIND 81 50 16 (20) 16 (20) 14 (17)
HS2 160 52 45 (28) 40 (25) 34 (21)
‘Human sera were from patients affected by multiple sclerosis (MS), other inflammatory neurologic diseases (OIND), non-inflammatory neurologic diseases (NIND) and
healthy subjects (HS1), (HS2).
*The prevalence of SV40 antibodies in MS patients is statistically significant lower that those detected in NIND patients (P=0.0254) and in HS1 (P=0.001), whereas no significant
was the different prevalence detected in MS and OIND patients (P.0.05).
** The prevalence of SV40 antibodies in OIND patients is statistically significant lower that those detected in HS2 (P=0.0403). The different prevalence of SV40 antibodies
between the cohorts of NIND patients was not significant compared with the HS2 (P.0.05). Statistical analysis was performed using the x2 test.
doi:10.1371/journal.pone.0110923.t002
SV40 in OIND Patients
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Our immunologic data suggest that specific SV40 antibodies are
detectable in human serum samples from neurologic patients and
healthy individuals.
The prevalence of SV40 antibodies observed in Italian patients
affected by MS and OIND, revealed a lower prevalence of SV40
antibodies in these patients respect to controls represented by
NIND patients and HS. Indeed, our serologic assays indicated that
the prevalence of SV40 antibodies in serum samples of patients
affected by MS (6%) is lower than that determined in HS1 (22%)
(P = 0.001) and in NIND patients (17%) (P = 0.0254). Similarly,
the prevalence of SV40 antibodies determined in OIND patients
(10%) is lower than that determined in HS2 (21%) (P = 0.04).
It should be noted that MS patients included in our study, at the
time of the serum collection, were not subjected to any immuno-
modulatory therapy. This data indicates that the low prevalence of
SV40 antibodies is not due to the immune-modulatory therapy.
It has been proposed that viruses may play a role in MS
pathogenesis acting as environmental triggers. However, it
remains to be elucidated whether viruses are causal agents of the
MS onset.
Our data represent the first study indicating a significant low
prevalence of serum antibodies against SV40 in patients affected
by inflammatory neurologic diseases, including MS. One may
speculate that these patients, with specific impairments of their
immune system, are poor responders to SV40 infection because
unable to present these polyomaviral antigens. In this peculiar
condition of the host, SV40 escaping from the immune
surveillance could exerts its pathologic effect in human oligoden-
drocytes. Indeed, SV40 is responsible in immunodepressed/
suppressed macaques of the PML, another inflammatory neuro-
logic disease related to the myelin degradation [15,16]. It should
be noted that SV40 in HIV-positive or AIDS patients does not
increase its viral load indicating that human cells are only semi-
permissive to its multiplication, whereas the inflammatory
molecules do not efficiently reactivate this polyomavirus
[30,31,32].
A recent investigation reported that the IgG levels in MS
patients against distinct herpesviruses do not differ from that of
controls, whereas a higher IgG prevalence against EBV was
detected [5]. Our immunologic data suggest that a specific
dysregulation in the IgG response to SV40 in multiple sclerosis
and OIND patients may occur. At present, the nature of this
immunologic defect is not known. It has been reported that the
cronic inflammation, which characterize these patients, is respon-
sible of several immune impairments [33]. The low level of SV40
antibodies detected in serum samples of MS patients could be
related to the cronic inflammatory conditions of these patients that
may affect the response/stability of SV40 antibody over time.
Figure 1. Serologic profile of serum antibody reactivity to SV40
mimotopes VP1 B (A) and VP2/3 C (B) and VPs B+C (C).
Immunologic data are from serum samples from Multiple Sclerosis
patients (MS), Healthy Subjects (HS1), Other Inflammatory Neurologic
Diseases (OIND), Non-Inflammatory Neurologic Diseases (NIND) and
Healthy subjects (HS2). Results are presented as values of optical
density (OD) readings at l 405 nm, of serum samples diluted at 1:20,
detected in indirect ELISA. In scatter dot plotting, each plot represents
the dispersion of OD values to a mean level indicated by the line inside
the scatter with Standard Error Mean (SEM) for each group of subjects
analyzed. A) The mean OD of sera (VP B 6 Std Error) in MS (0.3260.02)
were lower than that in HS1 (0.5060.02) and in OIND (0.6760.04).
Moreover the mean OD of sera in OIND were higher than that in NIND
(0.3260.02) and HS2 (0.4660.02). The mean OD of sera in NIND were
lower than that in HS2. B) The mean OD of sera (VP C 6 Std Error) in MS
(0.2660.03) were lower than that in HS1 (0.4360.02). C) The mean OD
of sera (VPs B+C 6 Std Error) in MS (0.2960.02) were lower than that in
HS1 (0.4660.02) and in OIND (0.4960.03). Moreover, the mean OD of
sera in OIND were higher than that in NIND (0.3460.02). The mean OD
in NIND were lower than that in HS2 (0.4360.02) and in OIND sera.
Statistical analysis was performed using Anova and Newman-Keuls
Comparison test. (**P,0.001; uP,0.01).
doi:10.1371/journal.pone.0110923.g001
SV40 in OIND Patients
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Alternatively, the low prevalence of SV40 antibodies detected in
these patients indicates that they are less prone to the SV40
infection, or a closely related yet unknown human polyomavirus.
Additional studies are needed to verify if SV40 plays a role in
the MS onset, such as the evaluation of the viral DNA load, virus
isolation, HLA characterization of the host and IgG isotype




A total of 591 serum samples were collected at the University
Hospital of Ferrara, Department of Neurology and Clinical
Laboratory Analysis. Human sera were from discarded clinical
laboratory analysis samples, anonymously collected, coded with
indications of age, gender and pathology, if any. Sera from MS
patients (n = 93), as well as from other inflammatory neurologic
(OIND) (n = 77), and non-inflammatory neurologic diseases
(NIND) (n = 81) affected patients and healthy subjects (HS) with
a different mean age, HS1, HS2 (n = 180, mean age = 40 yrs;
n = 160, mean age = 51 yrs, respectively) were analyzed for IgG
antibodies reacting to SV40 viral capsid protein (VP) mimotopes,
represented by synthetic peptides, which mimic VP antigens
(Table 1). To this purpose indirect ELISA was set up employing
synthetic peptides, which correspond to SV40 VP 1-2-3
mimotopes, together with an unrelated human peptide, hNPS,
employed as a negative control of the serum reactivity [34].
Informed written consent was obtained by patients/individuals.
The project was approved by the County Ethical Committee,
Ferrara, Italy.
Synthetic Peptides
Computer assisted analyses allowed us to select 2 specific SV40
peptides, from the late viral region by comparing the three capsid
proteins, VP 1-2-3 from SV40, with the amino acids of the human
BK (BKV) and JC (JCV) polyomaviruses which are highly
homologous to SV40, as well as with other, less homologous
polyomaviruses [20,22]. Previous ELISA results indicated that the
two SV40 peptides did not cross-react with the BKV and JCV
hyperimmune sera that were employed as controls [20,22]. The
two peptides belong to the VP1/VP2/VP3 viral capsid proteins
(VP1 ID: 1489598); VP3 ID: 9486895; web site, http://www.ncbi.
nlm.nih.gov/nuccore). The amino acid sequences of the two
peptides, known as VP1 B and VP2/3 C, respectively, are as
follows:
VP1 B: NH2- NPDEHQKGLSKSLAAEKQFTDDSP- COOH
VP2/3 C: NH2- IQNDIPRLTSQELERRTQRYLRD- COOH
VP1 B and VP2/3 C mimotopes were selected as they react
specifically in indirect ELISA with the rabbit hyperimmune serum
that had been experimentally immunized with SV40 (positive
control serum). SV40-positive and SV40-negative human sera
were also employed as controls. These SV40 control sera, selected
by the neutralization assay, were from our collections
[19,20,21,22] (see below the other technical details). BKV and
JCV hyperimmune rabbit sera did not react with VP1 B or VP2/3
C peptides (negative control sera). The amino acid residues of the
two specific SV40 VP peptides show low homology with the BKV,
JCV and other polyomaviruses VPs [20,22]. The characterization
of these two peptides were published before [20,22]. The synthetic
peptides were synthesized using standard procedures and were
purchased from UFPeptides s.r.l., Ferrara, Italy [20].
Indirect Enzyme-Linked Immunosorbent Assay (ELISA)
Indirect ELISA was developed and standardized to detect
specific antibodies against SV40 in human sera using VP1 B VP
2/3 C synthetic peptides [20,22]. Peptide coating. Plates were
coated with 5 mg of the selected peptide for each well and diluted
in 100 ml of Coating Buffer, pH 9.6 (Candor Bioscience,
Germany). Peptide blocking. Blocking was made with 200 ml/well
of the Blocking Solution, containing the casein (Candor Biosci-
ence, Germany) at 37uC for 90 min. Primary antibody adding.
Different wells were covered with 100 ml containing the following
sera: positive-control, represented by immune rabbit serum
containing anti-SV40 antibodies, negative controls represented
by immune sera anti-BKV and anti-JCV, and three human serum
samples, which were found to be SV40 negative in our previous
investigations [20,22]. Sera under analysis were diluted at 1:20 in
Low Cross-Buffer, pH 7.2 (Candor Bioscience, Germany). Sec-
ondary antibody adding. The solution contained a goat anti-
human IgG heavy and light chain specific peroxidase-conjugate
(Calbiochem-Merck, Germany) diluted 1:10,000 in Low Cross-
Buffer. Dye treatment and spectrophotometric reading. Samples
were treated with 100 ml of 2,2’-azino-bis 3-ethylbenzthiazoline-6-
sulfonic acid (ABTS) solution (Sigma-Aldrich, Milan) and then
read on the spectrophotometer (Thermo Electron Corporation,
model Multiskan EX, Finland) at a wavelength (l) of 405 nm. This
approach detects the color intensity in wells where the immuno-
complexes were formed by optical density (OD). Cut-off determi-
nation. The cut-off point was determined in each assay by an OD
reading of three negative controls, that were added to the standard
deviation and multiplied three times (+3SD). The choice of using
the mean plus 3 times the standard deviation is to eliminate false
positive samples and to increase the specificity of the ELISA test
Sera with antibodies against SV40 were considered VP-positive
upon reacting to both peptides of the late region and when sera
that had been analyzed three times, with independent experi-
ments, by indirect ELISA testing gave the same positive result.
SV40 specificity of the indirect ELISA employing synthetic
peptides which mimic the VPs antigens
In previous investigations, comparative computer assisted
analyses by BLAST program were carried out with the SV40
VP peptides B and C and the corresponding amino acid (a.a.)
sequences of the new human polyomaviruses (HPyV) and
hundreds of different BKV and JCV serotypes [20,22]. Results
indicate a low homology for the BKV and JCV prototypes and
other polyomaviruses. [20,22]. Indirect ELISA data indicate that
the two SV40 peptides B and C did not cross-react with the BKV
and JCV hyperimmune sera (negative controls), as described
before [20,22]. Briefly, hyperimmune sera against SV40 and BKV
were obtained in rabbits that had been inoculated with purified
viral stocks as previously reported [20]. The serum against JCV
was kindly provided by Dr. Major, NIH, Bethesda (MD), U.S.A
[20,22]. The immune serum anti-BKV was titered using a
hemagglutination inhibition (H.A.I.) test employing human
erythrocytes group 0, Rh+. Anti SV40 serum was titered by
neutralization assay [20].
SV40 VP1 B and VP2/3 C mimotopes were selected as they
react specifically in indirect ELISA with the rabbit hyperimmune
serum that had been experimentally immunized with SV40
(positive control) [20,22], and with SV40-positive human sera.
These SV40-positive human sera, from our collection, were
analyzed before by SV40 neutralization assay [19,20]. The human
peptide hNPS, a.a. sequence SFRNGVGTGMKKTSFQRAKS
[34] was employed as a negative control peptide [20,22].
SV40 in OIND Patients
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Serum samples tested by indirect ELISA diluted at 1/20 were
considered SV40-positive when above OD = 0.17–0.19, according
to the spectrophotometric reading. Indeed, this cut-off point
represents the value that discriminates SV40-negative (sample with
OD below 0.17–0.19) from SV40-positive samples (OD above
0.17–0.19). The positive controls, represented by the SV40
hyperimmune rabbit serum, had an OD of up to 1.8, while the
two JCV and BKV hyperimmune rabbit sera, which were
employed as negative controls, had an OD of less than 0.1. In
each ELISA plate 3 SV40-positive and 3 SV40-negative human
sera, from our collections [19,20,21,22] were also added. The
selection of these human sera was based on their SV40-
neutralization activity [19,20].
Statistical analyses
All analyses were performed by Prism 4.0 (GraphPad software).
For all tests, we considered P values , 0.05 to be statistically
significant. To determine significances between two groups we
used two-sided chi-square test. The serologic profile of serum
antibody reactivity to SV40 mimotopes was statistically analyzed
using Anova and Newman-Keuls Comparison test.
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